Page last updated: 2024-12-07

monocrotaline pyrrole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Monocrotaline pyrrole is a pyrrolizidine alkaloid metabolite produced by the hydrolysis of the naturally occurring plant toxin monocrotaline. It is a potent vasoconstrictor and has been implicated in the pathogenesis of pulmonary hypertension. Monocrotaline pyrrole is a reactive electrophile that can bind to and damage DNA. It is also a potent inhibitor of mitochondrial respiration. Its effects on the vascular system, including the constriction of blood vessels, have been studied extensively. Researchers investigate this compound due to its role in the development of pulmonary hypertension. This knowledge could lead to the development of new therapies for this potentially fatal condition.'

monocrotaline pyrrole: RN given refers to (13alpha,14alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104764
MeSH IDM0062386

Synonyms (23)

Synonym
2h-(,6)dioxacyclounlecino(2,3,4-gh)pyrrolizine-2,6(3h)-dione, 4,5,8,12,13,13a-hexahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r-(3r*,4r*,5r*,13ar*))-
3,8-didehydromonocrotaline
monocrotaline, 3,8-didehydro-
monocrotaline pyrrole
monocrotaline pyrrole metabolite
dehydromonocrotaline
20-norcrotalanan-11,15-dione, 3,8-didehydro-14,19-dihydro-12,13-dihydroxy-, (13-alpha,14-alpha)-
2h-(,6)dioxacyclounlecino(2,3,4-gh)pyrrolizine-2,6(3h)-dione, 4,5,8,12,13,13a-hexahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r,4r,5r,13ar)-
23291-96-5
1hw8c6svg7 ,
unii-1hw8c6svg7
ZONSVLURFASOJK-LLAGZRPASA-N
20-norcrotalanan-11,15-dione, 3,8-didehydro-14,19-dihydro-12,13-dihydroxy-, (13.alpha.,14.alpha.)-
(+)-dehydromonocrotaline
2h-(1,6)dioxacycloundecino(2,3,4-gh)pyrrolizine-2,6(3h)-dione, 4,5,8,12,13,13a-hexahydro-4,5-dihydroxy-3,4,5-trimethyl-, (3r,4r,5r,13ar)-
DTXSID80177860
dehydro monocrotaline
J-015066
(3r,4r,5r,13ar)-4,5-dihydroxy-3,4,5-trimethyl-4,5,8,12,13,13a-hexahydro-2h-[1,6]dioxacycloundeca[4,3,2-gh]pyrrolizine-2,6(3h)-dione
Q27896393
(1r,4r,5r,6r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.013,16]hexadeca-10(16),11-diene-3,7-dione
dehydro monocrotaline is known as a metabolite of the hepatotoxin monocrotaline.
dehydro monocrotaline, 90per cent

Research Excerpts

Overview

Monocrotaline pyrrole (MCTP) is a highly reactive pneumotoxic metabolite of the pyrrolizidine alkaloid plant toxin monocrotalin. It causes pulmonary vascular injury and right ventricular hypertrophy in rats.

ExcerptReferenceRelevance
"Monocrotaline pyrrole (MCTP) is a putative, toxic metabolite of the pyrrolizidine alkaloid, monocrotaline (MCT). "( Characterization of monocrotaline pyrrole-induced DNA cross-linking in pulmonary artery endothelium.
Petry, TW; Roth, RA; Wagner, JG, 1993
)
2.05
"Monocrotaline pyrrole (MCTP) is a highly reactive pneumotoxic metabolite of the pyrrolizidine alkaloid plant toxin monocrotaline. "( Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats.
Lappin, PB; Roth, RA,
)
1.78
"Monocrotaline pyrrole (MCTP) is a reactive metabolite of the plant toxin monocrotaline (MCT), which produces pulmonary vascular injury and right ventricular hypertrophy in rats. "( The effect of dietary restriction and altered sodium intake on the cardiopulmonary toxicity of monocrotaline pyrrole.
Fink, GD; Ganey, PE; Roth, RA, 1985
)
1.93
"Monocrotaline pyrrole (MCTP) is a reactive metabolite of the pyrrolizidine alkaloid monocrotaline. "( Lack of effect of deferoxamine, dimethyl sulfoxide, and catalase on monocrotaline pyrrole pulmonary injury.
Bruner, LH; Carpenter, LJ; Johnson, K; Roth, RA, 1987
)
1.95
"Monocrotaline pyrrole (MCTP) is a pyrrolizidine alkaloid that causes pulmonary vascular injury and pulmonary hypertension in rats. "( The effect of immunosuppressants and adoptive transfer in monocrotaline pyrrole pneumotoxicity.
Bruner, LH; Bull, RW; Roth, RA, 1987
)
1.96
"Monocrotaline pyrrole (MCTP) is a reactive metabolite of the pyrrolizidine alkaloid monocrotaline. "( Injury to the isolated, perfused lung by exposure in vitro to monocrotaline pyrrole.
Hilliker, KS; Roth, RA, 1985
)
1.95

Treatment

ExcerptReferenceRelevance
"The monocrotaline pyrrole (MCTP)-treated rat is a useful model for the study of certain chronic pulmonary vascular diseases. "( Cellular fibronectin and von Willebrand factor concentrations in plasma of rats treated with monocrotaline pyrrole.
Emeis, JJ; Roth, RA; Schultze, AE, 1996
)
1.07

Toxicity

ExcerptReferenceRelevance
" It is well established that the pneumotoxicity of MCT depends on its hepatic bioactivation to monocrotaline pyrrole (MCTP) and perhaps other toxic metabolites."( Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity.
Bruner, LH; Carpenter, LJ; Hamlow, P; Roth, RA, 1986
)
0.73
" We hypothesized that metabolic activation of MCT by mixed-function oxygenases (MFO) to dehydromonocrotaline (MCTP) is a prerequisite for its immunotoxicity, as has been shown for other toxic effects of MCT."( Role of metabolism in monocrotaline-induced immunotoxicity in C57BL/6 mice.
Buhler, DR; Deyo, JA; Kerkvliet, NI; Reed, RL,
)
0.13
" These results suggest that the toxic effect of MCT on hepatocytes may be caused by metabolite-induced mitochondrial energetic impairment, together with a decrease of cellular glutathione and protein thiols."( Cytotoxicity of monocrotaline in isolated rat hepatocytes: effects of dithiothreitol and fructose.
Alves, LC; Garcia, AF; Maioli, MA; Mingatto, FE; Perandin, D; Pereira, FT, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" At a dosing regimen of KET that inhibited the 5-HT-induced platelet shape change in platelet-rich plasma and the 5-HT-induced increase in perfusion pressure in isolated lungs, KET did not affect the elevation in lung weight or the increased accumulation of 125I-albumin in the lung tissue of MCTP-treated rats."( Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
Ganey, PE; Hadley, KB; Roth, RA; Sprugel, KH, 1986
)
1.71
" Finally, the Tx receptor antagonist L-640,035 was tested using a dosing regimen that reduced the increase in right ventricular pressure caused by a stable endoperoxide analogue in MCTP-treated rats."( Thromboxane does not mediate pulmonary vascular response to monocrotaline pyrrole.
Ganey, PE; Roth, RA, 1987
)
0.52
" This study aimed to reveal whether partial pressure of oxygen of blood determined the binding and release of monocrotaline pyrrole from erythrocytes in rats with one subcutaneous injection of monocrotatline at the standard dosage of 60 mg/kg."( Monocrotaline pyrrole induces pulmonary endothelial damage through binding to and release from erythrocytes in lung during venous blood reoxygenation.
Dupuis, J; Fang, J; Hu, Q; Jing, ZC; Li, J; Lu, Y; Luo, S; Su, Y; Wang, T; Xiao, R; Zhang, J; Zhu, L, 2019
)
2.17
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (121)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (23.14)18.7374
1990's50 (41.32)18.2507
2000's22 (18.18)29.6817
2010's17 (14.05)24.3611
2020's4 (3.31)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 14.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index14.87 (24.57)
Research Supply Index4.85 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (14.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (2.36%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other124 (97.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]